Small Molecules

24 Jun 2023 Inversago Pharma Presents Data from Phase 1b Trial of INV-202, a Peripheral CB1r Blocker for Metabolic Syndrome, at the 83rd American Diabetes Association Scientific Sessions
24 Jun 2023 FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata
24 Jun 2023 Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight
24 Jun 2023 Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development
23 Jun 2023 Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Liver Cancer Trial Using TTI-101, a Novel STAT3 Inhibitor
23 Jun 2023 SELLAS Announces First Patient Dosed in Phase 2a Clinical Trial of GFH009 in Acute Myeloid Leukemia
22 Jun 2023 AceLink Therapeutics Receives FDA Clearance to Initiate a Phase 2 Study of AL1211 in Patients with Fabry Disease
21 Jun 2023 U.S. FDA Approves First Anti-Inflammatory Drug for Cardiovascular Disease
21 Jun 2023 Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies
21 Jun 2023 Escient Pharmaceuticals Announces Positive Results from Phase 1 Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders
21 Jun 2023 Enanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
21 Jun 2023 Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat
21 Jun 2023 Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval
19 Jun 2023 Allgenesis Announces Encouraging Phase 1b Data Showing AG-80308 Providing Improvements in Multiple Signs and Symptoms in Dry Eye Patients
18 Jun 2023 Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress
18 Jun 2023 Sling Therapeutics Presents Data Demonstrating Linsitinib Prevents Thyroid Eye Disease Progression in a Mouse Model at ENDO 2023
16 Jun 2023 UPDATE: Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure
15 Jun 2023 Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS
15 Jun 2023 Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications
15 Jun 2023 Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor
15 Jun 2023 Mithra Announces New Positive Preclinical Data from CSF-1R Inhibitor Program
15 Jun 2023 MindRank Announces First-in-Human Phase 1 Study of MDR-001 in China
15 Jun 2023 Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders
14 Jun 2023 EyeBio Announces First Patients Dosed in Phase 1b/2 Trial of Restoret™ in Neovascular Age Related Macular Degeneration and Diabetic Macular Edema
14 Jun 2023 U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up